Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.09 is 41% above its 5-year average of -6.97, near the high end of its 5-year range (-12.89–-2.34).
57.61% below its 12-month average of -2.59.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.02.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
EARNINGS PER SHARE (EPS)
-4.09
EARNINGS PER SHARE (EPS) AVG TTM
-2.59
EARNINGS PER SHARE (EPS) AVG 3Y
-6.03
EARNINGS PER SHARE (EPS) AVG 5Y
-6.97
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-57.61%
CURRENT VS 3Y AVG
+32.14%
CURRENT VS 5Y AVG
+41.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
LENZ Therapeutics, Inc.
Market Cap
$116.80M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$116.54M
Earnings Per Share (EPS)
-1.08
TTM Avg
-1.62
3Y Avg
-1.56
5Y Avg
-1.43
Market Cap
$117.86M
Earnings Per Share (EPS)
-1.52
TTM Avg
-3.16
3Y Avg
-3.35
5Y Avg
-6.72
Market Cap
$114.62M
Earnings Per Share (EPS)
-0.33
TTM Avg
-0.41
3Y Avg
-0.34
5Y Avg
-0.29
Market Cap
$114.34M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
Market Cap
$120.36M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.92
3Y Avg
-84.40
5Y Avg
-674.41
Market Cap
$120.58M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
Market Cap
$113.70M
Earnings Per Share (EPS)
-0.47
TTM Avg
-0.87
3Y Avg
-1.14
5Y Avg
-0.92
Market Cap
$112.01M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $116.80M | -4.09 | -2.59 | -6.03 | -6.97 |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | -1.08 | -1.62 | -1.56 | -1.43 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.86M | -1.52 | -3.16 | -3.35 | -6.72 |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | -0.33 | -0.41 | -0.34 | -0.29 |
| Genelux Corporation (GNLX)vs › | $114.34M | -0.89 | -0.91 | -0.79 | -0.74 |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.36M | -0.54 | -0.92 | -84.40 | -674.41 |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -0.28 | -1.88 | -2.46 | -1.80 |
| Lucid Diagnostics Inc. (LUCD)vs › | $113.70M | -0.47 | -0.87 | -1.14 | -0.92 |
| Coya Therapeutics, Inc. (COYA)vs › | $112.01M | -1.07 | -1.13 | -1.07 | -0.91 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.56M | -0.99 | -1.38 | -1.93 | -2.07 |
Trailing EPS (TTM)
$-4.09
Forward EPS (Est.)
$-4.18
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.85 |
| 2024-12-31 | -2.34 |
| 2022-12-31 | -12.89 |
| 2021-12-31 | -8.54 |
| 2020-12-31 | -8.24 |
| 2019-12-31 | -0.01 |
